

Date: 14<sup>th</sup> February, 2018

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001.  
Scrip Code: 511523

**Sub.: Unaudited Financial Results for the quarter ended December 31, 2017**

Dear Sir,


This is to inform that the Board of Directors of the Company at its meeting held today, has inter alia, approved Unaudited Financial Results for the quarter ended December 31, 2017. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following documents:

1. Statements showing Unaudited Financial Results for the quarter ended December 31, 2017;
2. Limited Review Report on the Unaudited Financial Results for the quarter ended December 31, 2017.

Please acknowledge.

Thanking You.

Yours faithfully,  
For Veerhealth Care Limited



Bhavin S. Shah  
Managing Director  
DIN: 03129574

Encl: As above

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Statement of Unaudited Financial Results for the Quarter / Nine Months ended December 31, 2017

(Rs. in lakhs)

Sr. No.	Particulars	Standalone				
		Quarter ended 31-12-2017	Quarter ended 30-09-2017	Quarter ended 31-12-2016	Nine Months ended 31-12-2017	Nine Months ended 31-12-2016
I	Revenue from operations	151.18	130.12	89.80	351.20	148.61
II	Other Income	22.06	24.97	22.44	59.73	42.42
III	<b>Total Revenue (I + II)</b>	<b>173.24</b>	<b>155.09</b>	<b>112.24</b>	<b>410.93</b>	<b>191.03</b>
IV	<b>Expenses:</b>					
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	105.61	68.18	38.87	222.67	114.95
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-15.54	-3.17	17.94	-22.03	-55.88
	(d) Employee benefits expense	17.12	13.00	16.48	42.28	42.98
	(e) Finance Costs	1.71	1.82	2.32	5.5	7.98
	(f) Depreciation and amortisation expens	7.81	6.21	5.76	19.64	17.15
	(g) Other expenses	25.34	18.23	17.73	52.35	36.70
	<b>Total Expenses</b>	<b>142.05</b>	<b>104.27</b>	<b>99.10</b>	<b>320.41</b>	<b>163.88</b>
V	<b>Profit/(Loss) before exceptional and extraordinary items (III - IV)</b>	<b>31.19</b>	<b>50.82</b>	<b>13.14</b>	<b>90.52</b>	<b>27.16</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit before extraordinary items and tax (V - VI)</b>	<b>31.19</b>	<b>50.82</b>	<b>13.14</b>	<b>90.52</b>	<b>27.16</b>
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit before tax (VII - VIII)</b>	<b>31.19</b>	<b>50.82</b>	<b>13.14</b>	<b>90.52</b>	<b>27.16</b>
X	Tax expense:					
	1) Current Tax	0.00	0.00	0.00	0.00	0.00
	2) Deferred Tax	0.00	0.00	0.00	0.00	0.00
XI	<b>Profit/(Loss) for the period from continuing operations (IX - X)</b>	<b>31.19</b>	<b>50.82</b>	<b>13.14</b>	<b>90.52</b>	<b>27.16</b>
XII	Profit/(Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIII	Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV	<b>Profit/(Loss) for the period (XI + XIV)</b>	<b>31.19</b>	<b>50.82</b>	<b>13.14</b>	<b>90.52</b>	<b>27.16</b>
XVI	<b>Other Comprehensive Income</b>					
	(a) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00	0.00
	<b>Total Other Comprehensive Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
	<b>Total Comprehensive Income for the period (Net of Tax)</b>	<b>31.19</b>	<b>50.82</b>	<b>13.14</b>	<b>90.52</b>	<b>27.16</b>
XVII	Earnings per equity share:					
	a. Basic	0.45	0.73	0.19	1.31	0.39
	b. Diluted	0.45	0.73	0.19	1.31	0.39
XVIII	Paid-up equity share capital (Face Value of the Share)	693.42 Rs. 10/-	693.42 Rs. 10/-	693.42 Rs. 10/-	693.42 Rs. 10/-	693.42 Rs. 10/-

*Trasinska*

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

NOTES:


- 1 The above financial results were reviewed by the Audit Committee and taken on record by Board of Directors at their meeting held on 14th February, 2018.
- 2 The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015.
- 3 The Company has adopted Indian Accounting Standards (Ind AS) with the transition date of April 01, 2016. Accordingly, the financial results for the quarter / nine months ended December 31, 2016 and December 31, 2017 have been prepared in accordance with the recognition and measurement principles laid down in Ind-AS 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016. The reconciliation of net profit for the quarter / nine months ended December 31, 2016 under Ind AS and previous GAAP is as follows:

(Rs. in lakhs)

Description	Quarter ended on 31/12/2016	Nine Months ended 31/12/2016
Net Profit as per previous Indian GAAP	13.17	27.24
Add : On account of unwinding of interest	-0.03	-0.08
Net Profit as per Ind-AS	13.14	27.16
Other Comprehensive Income (Net of tax)	-	-
Total Comprehensive Income	13.14	27.16

- 4 The Company has one segment of activity namely "Ayurved Pharma Products".
- 5 Results for the quarter and year ended March 31, 2017 under Ind AS have not been given as the Company has availed exemption provided by SEBI Circular dated July 5, 2016.
- 6 Figures of previous period / year have been regrouped / rearranged wherever necessary.
- 7 The financial results of the Company are available at www.bseindia.com, at www.mseil.in and at www.veerhealthcare.net.

By order of the Board  
For Veerhealth Care Limited



Bhavin S. Shah  
Managing Director  
DIN: 03129574

Place: Ahmedabad  
Date: 14th February, 2018



**Limited Review Report**

**To the Board of Directors of Veerhealth Care Limited**

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of M/s. Veerhealth Care Limited ("the Company") for the quarter/ nine months ended December 31, 2017 which are included in the accompanying Statement of Standalone unaudited financial results for the quarter/ nine months ended December 31, 2017 together with the notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Further, the Management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company's opening unaudited Balance Sheet as at April 01, 2016 (transition date) prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind As) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the statement based on our review.

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to Note 3 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 01, 2017, and accordingly, the Statement has been prepared by the Company's Management in compliance with Ind AS.

**For M. H. Dalal & Associates**  
**Chartered Accountants**  
**FRN: 112449W**

**Devang M. Dalal**  
**Partner**

**M. No. 109049**

**Place: Mumbai**

**Date: 14<sup>th</sup> February, 2018**

